Company intelligence / Profile preview
Meiji Holdings Co., Ltd.
Chuo-ku, Tokyo, Japanmeiji.com ↗
- Ownership
- Public · 2269
- Employees
- ~5500
- Development stage
- Commercial
01
Overview
Meiji has multiple commercial products including antibacterial drugs, CNS medications, and recently obtained the world's first marketing approval for a self-amplifying mRNA vaccine against COVID-19 (Kostaive®). They also have launched a selective ROCK2 inhibitor (belumosudil mesilate) for chronic GVHD and an HDAC inhibitor (tucidinostat) for ATLL and PTCL in Japan[9].
- Therapeutic areas
- OncologyImmunologyHematologyPsychiatryDermatologyNeurologyInfectious Diseases
- Modalities
- Small moleculesmRNA vaccinesantibacterial drugsbiologics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
MPM BioImpactKOI The Cambodia
Beyond the preview
Go deeper on Meiji Holdings Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meiji Holdings Co., Ltd..